Christine Mikail Cvijic - 06 Jul 2026 Form 4 Insider Report for Neurogene Inc. (NGNE)

Reporting relationship: President and CFO, Director
Issuer ticker: NGNE
Reported as of: 06 Jul 2026
Net transaction value: -$173,375
SEC form: 4
Accepted by SEC: 07 Jul 2026, 21:08:32 UTC
Prior SEC filing: 02 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Donna M. Cochener as attorney-in-fact for Christine Mikail Cvijic

Key filing fact

Christine Mikail Cvijic filed Form 4 for Neurogene Inc. (NGNE) on 07 Jul 2026.

Key facts

This page summarizes Christine Mikail Cvijic's Form 4 filing for Neurogene Inc. (NGNE).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 07 Jul 2026, 21:08.

Change

Previous filing in this sequence was filed on 02 Jul 2026.
Current net transaction value: -$173,375.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001543663 Primary reporting owner

Cvijic Christine Mikail

Relationship: President and CFO, Director
Address: C/O NEUROGENE INC., 535 W 24TH STREET, 5TH FLOOR, NEW YORK
Signature: /s/ Donna M. Cochener as attorney-in-fact for Christine Mikail Cvijic
Signature date: 07 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NGNE transaction

Common Stock

Sale

Transaction value: $21,613
Shares: -600
Change %: -0.68%
Price: $36.02
Shares after: 88,240
Date: 06 Jul 2026
Ownership: Direct
Footnotes: F1, F2, F3

NGNE transaction

Common Stock

Sale

Transaction value: $151,763
Shares: -4,200
Change %: -4.8%
Price: $36.13
Shares after: 84,040
Date: 07 Jul 2026
Ownership: Direct
Footnotes: F1, F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 4 footnotes

Footnote F1

The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025. Shares sold were held jointly by the reporting person and her spouse, David Cvijic.

Footnote F2

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.035, inclusive. The reporting person undertakes to provide Neurogene Inc. (the "Company"), any securityholder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F3

Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 13,533 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Following completion of all sales reported on this Form 4, the reporting person no longer holds any shares jointly with her spouse.

Footnote F4

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.455, inclusive. The reporting person undertakes to provide the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.